Nirsevimab-alip Injection - An Overview

What Is Nirsevimab-alip?

Nirsevimab-alip is used to prevent serious respiratory infections caused by the respiratory syncytial virus. It is primarily used for newborn babies as well as infants less than one year of age and is administered during or before their first RSV season. Nirsevimab-alip medication can also be administered to babies up to 24 months of age if they are still at risk during their second RSV seasonal exposure. This medication is used as it can provide pre-made antibodies to the body. These antibodies help to fight RSV infection.

RSV infection can bring about serious respiratory complications. These problems include pneumonia and bronchitis. However, in some infections, RSV can be fatal. Babies under the age of six months are most susceptible to RSV infections. Babies who have respiratory problems or pulmonary disease are also prone to RSV. Premature babies are highly susceptible to RSV infections. Babies with congenital problems of the heart are also most susceptible to RSV infections.

Drug Composition:

• Active Ingredient: Nirsevimab-alip.

• Other Ingredients: Arginine hydrochloride, L-histidine hydrochloride monohydrate, histidine, polysorbate 80, sucrose, and water for injection.

What Are the Indications of Nirsevimab-Alip?

Nirsevimab-alip is used to help prevent serious lung infections caused by RSV (respiratory syncytial virus) in:

• Newborns and babies who are born or entering their first RSV season.

• Children under two years old who are still at risk of severe RSV infections during their second RSV season.

What Are the Contraindications of Nirsevimab-alip Injection?

Infants and children with a history of severe allergic reactions, including anaphylaxis, to Nirsevimab-alip itself or any of the ingredients in the vaccine should not receive it.

What Is the Dosage of Nirsevimab-alip Injection?

Nirsevimab-alip is available as a prefilled intramuscular injection in two strengths:

• 50 mg per 0.5 mL prefilled syringe.

• 100 mg per mL prefilled syringe.

• The injection is given once per RSV season to prevent serious RSV lung infections.

Dosage for First RSV Season

• Babies weighing less than 11 pounds: One injection of 50 mg.

• Babies weighing 11 pounds or more: One injection of 100 mg.

Dosage for Second RSV Season (High-Risk Children)

Children under 24 months who remain at risk:

A total dose of 200 mg, administered as two separate 100 mg injections.

Children Undergoing Heart Surgery

• If heart surgery occurs within 90 days of receiving Nirsevimab-alip, an additional dose should be given based on the child’s current weight.

• If surgery occurs after 90 days, a supplemental dose ranging from 50 mg to 200 mg may be required, as advised by the physician.

Children with Kidney or Liver Problems

• No dose adjustment is required, as kidney or liver conditions do not affect the action of Nirsevimab-alip.

For Patients:

How Does Nirsevimab-Alip Work?

Nirsevimab-alip comes as an injection, which provides the body with an antibody. The antibody helps protect the body against the RSV virus by fighting it. The antibody prevents lung infections. It prevents lung complications associated with breathing. The antibody works by preventing lung infections, which occur after five months.

The time spans one entire season because it occurs once in a season. The injection helps prevent hospitalisations associated with the RSV virus. The shot helps make the severity of the disease less because it occurs when one contracts the virus. The shot has not been tested in children who are older than two years.

How Effective Is Nirsevimab-alip Injection?

Nirsevimab-alip injection is highly effective in preventing RSV infection. This immunoglobulin product helps in the protection of the lungs from severe RSV disease. The protection given to the lungs from severe RSV disease lasts for at least five months. This usually includes the whole RSV seasonal year. The use of Nirsevimab-alip injection may lower the incidence of severe RSV disease by about 80 percent. This immunoglobulin product may lower the incidence of hospitalisation. This product also lowers the incidence and severity of breathing difficulties related to RSV disease.

What to Tell the Doctor Before Nirsevimab-alip Injection?

Discuss with the doctor or pharmacist if the child has allergy problems with Nirsevimab, other drugs, or any substance in the injection. The patient may also consult the pharmacist or read the medication guide for a list of ingredients.

How Is Nirsevimab-alip Injection Administered?

The drug Nirsevimab-alip is given via injection into a muscle of the thigh by the child's health care provider.

Administration of Nirsevimab-alip should be done in children during the RSV season. In such seasons, most cases of RSV infections take place. This falls into the periods of fall through spring.

Even after getting Nirsevimab-alip, the child may still catch RSV. Ask the healthcare provider about the signs and symptoms to watch for.

If the child has heart surgery, they may need another Nirsevimab-alip shot soon after the surgery.

What Are the Side Effects of Nirsevimab-alip Injection?

Common side effects of Nirsevimab-alip include rash and pain, swelling, or firmness where the shot was given. These are not all the possible side effects. Contact the doctor for advice if anything concerning is noticed.

Serious allergic reactions have occurred with medicines similar to Nirsevimab-alip. Seek medical help immediately if the child shows any of these symptoms:

• Swelling of the face, mouth, or tongue.

• Skin, lips, or nails turning bluish.

• Trouble swallowing or breathing.

• Muscle weakness.

• Unresponsiveness.

• Severe rash, hives, or itching.

Dietary Considerations: Make sure to follow the doctor's advice about any limits on what a person can eat, drink, or do.

Missed Dose: Nirsevimab is given as one injection, so the person does not need to take it every day.

Overdose:

There is not much information about Nirsevimab-alip overdose. There is no special treatment for it. If a person overdoses on the drug, then they should be closely watched for any side effects and given treatment to manage the symptoms if needed.

Storage:

Nirsevimab-alip should be refrigerated at 36°F (degrees Fahrenheit) to 46°F ( 2 to 8 degrees Celsius). It can stay at room temperature (68°F to 77°F or 20°C to 25°C) for up to eight hours, but if taken out of the fridge, it must be used within eight hours or thrown away. Store it in its original packaging to protect it from light until the person is ready to use it. Do not freeze, shake, or expose it to heat.

For Doctors

What Are the Pharmacological Aspects of Nirsevimab-alip Injection?

Mechanism of Action:

Nirsevimab-alip is a synthetic biologic product that is a monoclonal antibody targeting respiratory syncytial virus (RSV). After injection, the antibody links with the RSV virus and prevents its entry into healthy lung cells. It prevents the virus from infecting cells, thus preventing the virus from replicating in the lungs.

This helps prevent the airways and, by extension, the lungs from being severely damaged by RSV infections, which can cause conditions like pneumonia or bronchitis. The protection afforded by one dose lasts up to five months.

Pharmacodynamics:

Blood concentrations above 12.8 mg*day/mL of Nirsevimab-alip were associated with reduced lower respiratory illness for medically attended RSV infections. Immediately following intramuscular injections of Nirsevimab-alip, levels of anti-RSV antibodies in adults' blood remained at approximately fourfold compared with baseline levels, peaking on day six post-injection at eight hours after injection. It cannot be known whether the drug is safe and effective for use in adults. Clinical data have demonstrated that one dose of Nirsevimab-alip will protect up to five months.

Pharmacokinetics:

Nirsevimab-alip is consistently absorbed and metabolized in equal amounts when administered as a single muscle injection, both when the dose administered is 25 mg (half the lowest recommended dose) or 200 mg in children. The levels of Nirsevimab-alip in blood were comparable in the control versus the recommended dose between newborn and infant participants during their first RSV season and between those born before 35 weeks of gestation during their first RSV season, as well as between young children with chronic lung disease or congenital heart disease during both their first and second RSV seasons.

• Absorption: About 84 percent of Nirsevimab-alip is absorbed into the bloodstream, and it takes about six days to reach its highest levels, although this can vary from one to 28 days.

• Distribution: In a five kg infant, the total volume of distribution for Nirsevimab-alip is estimated to be 477 mL.

• Elimination: The drug has a half-life of about 71 days, meaning it takes that long for half of it to leave the body, and it is cleared at a rate of 3.42 mL per day for a five-kg infant.

• Metabolism: Nirsevimab-alip breaks down into smaller pieces through natural processes in the body.

Toxicity: There have not been any studies on the potential for Nirsevimab-alip to cause cancer, genetic changes, or reproductive issues.

Clinical Studies:

Clinical trials were conducted to assess Nirsevimab-alip in newborns and young children. It was done to see how well the medicine can prevent RSV infection. Fewer severe cases of the infection were seen in the results. Fewer children required hospital care. The medicine resulted in effectiveness during the RSV season, with protection lasting for several months. Most children endured the injection well. The side effects were mild. These studies helped confirm its safety and benefit in young children.

Warnings and Precautions:

• Allergic Reactions, Including Anaphylaxis: Serious allergic reactions, like anaphylaxis, have been seen with other similar medications (IgG1 monoclonal antibodies). If a severe allergic reaction occurs, appropriate medications or supportive care should be started right away.

• Use in People with Bleeding Disorders: Nirsevimab-alip, like other injections into muscle, should be given carefully to infants and children who have low platelets (thrombocytopenia), bleeding disorders, or are on blood thinners.

What Are the Drug Interactions of Nirsevimab-alip Injection?

Nirsevimab-alip does not affect RSV tests that use RT-PCR (reverse transcription polymerase chain reaction) or rapid antigen detection methods with antibodies targeting specific parts of the RSV fusion (F) protein. If an RSV test result is negative but the symptoms still suggest an RSV infection, it is recommended to confirm the diagnosis with an RT-PCR test.

Specific Considerations:

• Pregnancy and Lactation: Nirsevimab-alip is not intended for use in women who are of childbearing age.

• Pediatric Use: Nirsevimab-alip has been proven safe and effective in preventing RSV lung infections in newborns and babies entering their first RSV season, as well as in children up to 24 months old who are still at risk during their second RSV season. Its safety and effectiveness are supported by thorough studies in babies from birth to 12 months, along with data for children up to 24 months. However, its safety and effectiveness have not been established for children older than 24 months.